A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
Clinical trial NCT05249101 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05249101
- Sponsor
- CG Pharmaceuticals, Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-15
- Primary completion
- 2026-06-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.